Alto Neuroscience (NYSE:ANRO) Posts Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Alto Neuroscience (NYSE:ANRO) released its quarterly earnings data on Wednesday. The company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.08, FiscalAI reports.

Alto Neuroscience Price Performance

Shares of NYSE:ANRO traded down $1.48 during midday trading on Friday, reaching $30.82. 57,990 shares of the company’s stock traded hands, compared to its average volume of 367,339. The company has a fifty day simple moving average of $25.70 and a two-hundred day simple moving average of $22.68. Alto Neuroscience has a 1 year low of $3.05 and a 1 year high of $33.67. The company has a market cap of $1.08 billion, a P/E ratio of -12.71 and a beta of 1.06. The company has a debt-to-equity ratio of 0.07, a quick ratio of 20.52 and a current ratio of 20.52.

Wall Street Analyst Weigh In

Several research firms have commented on ANRO. Wall Street Zen lowered shares of Alto Neuroscience from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. HC Wainwright restated a “buy” rating on shares of Alto Neuroscience in a research note on Wednesday, June 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a report on Wednesday, July 29th. Chardan Capital reissued a “buy” rating and issued a $30.00 price target on shares of Alto Neuroscience in a report on Wednesday, April 22nd. Finally, Bank of America assumed coverage on shares of Alto Neuroscience in a research note on Tuesday, May 5th. They set a “buy” rating and a $35.00 price objective on the stock. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $36.62.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd boosted its stake in shares of Alto Neuroscience by 32.2% in the fourth quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock worth $371,000 after acquiring an additional 5,078 shares during the last quarter. Ikarian Capital LLC lifted its stake in shares of Alto Neuroscience by 368.2% in the fourth quarter. Ikarian Capital LLC now owns 515,000 shares of the company’s stock worth $9,167,000 after buying an additional 405,000 shares in the last quarter. Vestal Point Capital LP increased its stake in shares of Alto Neuroscience by 161.6% in the 4th quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after acquiring an additional 1,535,000 shares during the last quarter. Wellington Management Group LLP purchased a new position in shares of Alto Neuroscience during the 4th quarter worth $1,228,000. Finally, Millennium Management LLC boosted its position in shares of Alto Neuroscience by 99.5% during the 4th quarter. Millennium Management LLC now owns 629,985 shares of the company’s stock valued at $11,214,000 after acquiring an additional 314,227 shares during the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.